In this section
RICHMOND, Va., Feb 8, 2002 (BW HealthWire) -- Insmed Incorporated (Nasdaq: INSM) today announced that Geoffrey Allan, Ph.D., President and Chief Executive Officer, will present an overview of the Company to the Wall Street Analyst Forum 43rd Institutional Investor Conference on Monday, February 11, 2002 at 9:30 a.m. (EST) at The Roosevelt Hotel in New York. The presentation will be accessible online live and archived for replay in the investor relations section of the company's web site at www.insmed.com .
About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of type 2 diabetes and other metabolic and endocrine disorders. The Company's lead product candidate, INS-1, is an orally active small molecule that restores insulin sensitivity to tissue. The Company is developing INS-1 for the treatment of type 2 diabetes and polycystic ovary syndrome, a significant women's health disorder. In conjunction to INS-1, the Company is developing SomatoKine®, a recombinant human protein that is targeted towards the management of both type 1 and type 2 diabetics who are less sensitive to insulin therapy. Further information is available at www.insmed.com . Statements included within this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause actual results to differ materially from those described herein. Risks and uncertainties include: product candidates may fail in the clinic or may not be successfully marketed; lack of financial resources to complete development of clinical candidates; and competing products.
CONTACT: Insmed Incorporated, Richmond Baxter Phillips, III, 804/565-3041; email@example.com URL: http://www.businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page.